site stats

Cpg 7909 patent

WebApr 15, 2008 · CPG 7909 is an oligodeoxynucleotide containing immunostimulatory CpG motifs that activate human B and plasmacytoid dendritic cells via Toll-like receptor 9. We previously reported that addition of CPG 7909 to a commercial HBV vaccine enhanced the kinetics, magnitude, and longevity of the seroprotective response over 48 weeks. Web1.22 “ CpG 7909 ” means the Adjuvant Controlled by Coley that is a proprietary immunomodulatory oligonucleotide containing unmethylated cytosine and guanine dinucleotides whose sequence has been defined by Coley as CpG 7909 which acts as an agonist of toll-like receptor 9 to modulate the immune response.

CpG 7909: PF 3512676, PF-3512676 - PubMed

WebCpG ODN, type B (human) - TLR9-based adjuvant. CpG ODN 2006 (ODN 7909) is a synthetic immunostimulatory oligonucleotide (ODN) that contains unmethylated CpG dinucleotides. ODN 2006 is a class B CpG ODN and is a ligand of choice for human TLR9. It strongly activates B cells but weakly stimulates IFN-α secretion in pDCs. WebAug 1, 2004 · For example, CpG 7909 (PF-3512676 or ODN2006), a 24-mer-B-Class CpG ODN and known TLR9 agonists, can induce the production of TNF-α and stimulate and … explain black swan movie https://jdmichaelsrecruiting.com

Vaccine adjuvants: Understanding the structure and mechanism …

WebFeb 14, 2024 · In Phase 1A, seven Amph modified KRAS and NRAS peptides, G12D, G12R, G12V, G12A, G12C, G12S, G13D (Amph-Peptides 7P) will be evaluated in combination with recommended Phase 2 dose of Amph-CpG-7909 (10.0mg). This Amph-CpG-7909 dose will be evaluated with two Amph-Peptides 7P dose levels (1.4mg and 4.9mg) in 6 subjects … WebCpG 7909, acting through the TLR9 receptor present in B cells and plasmacytoid dendritic cells, stimulates human B-cell proliferation, enhances antigen-specific antibody production and induces interferon-alpha production, interleukin-10 … WebJan 15, 2005 · CpG oligodeoxynucleotides (CpG-ODNs) affect innate and adaptive immune responses, including antigen presentation, costimulatory molecule expression, dendritic cell maturation, and induction of cytokines enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). explain block cipher and stream cipher

CPG 7909 adjuvant improves hepatitis B virus vaccine... : AIDS

Category:VELOCITY: An Anthrax Vaccine Clinical Study - Full Text View ...

Tags:Cpg 7909 patent

Cpg 7909 patent

WO2024042830A1 - 一种重组人乳头瘤病毒疫苗组合物及其用途 - Google Patents

WebCpG ODN佐剂为一类已知具有佐剂特性的免疫刺激性寡聚核苷酸，能激活B细胞、NK、DC树突状等细胞，诱导释放IL-12、IFN-γ，从而诱导强Th1型应答和细胞免疫。 该种佐剂也是本领域技术人员所熟知的，已经在现有技术，例如国际申请已经在例如WO 96/02555、WO 99/33488中描述过。 目前已有一些商业化的CpG ODN佐剂，例如CpG 7909... WebIt confers an immediate nonspecific mechanism of protection through pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), nucleotide-binding, oligomerization domain (NOD)-like receptors (NLRs), …

Cpg 7909 patent

Did you know?

WebCpG 7909 [PF-3512676] is an immunomodulating synthetic oligonucleotide designed to specifically agonise the Toll-like receptor 9 (TLR9). It is being developed for the … WebAug 12, 2002 · Experimental: CPG 7909 Injection. Drug: CPG 7909. In the phase I portion of the protocol, patients will be included in escalating dose groups: 0.08, 0.12, 0.16, 0.36, 0.54 or 0.81 mg/kg of CPG 7909 Injection. Patients will be treated once weekly subcutaneously for 24 weeks. In the Phase II portion of the trial patients will be treated at the ...

WebCpG TLR9 antagonist technologies. Three US patents relating to CpG 7909 and the use of certain oligonucleotides for treating cancer are due to expire in 2014. Coley also has … WebJan 7, 2008 · CPG 7909 was licensed by Pfizer Pharmaceuticals Inc. (New York, NY, USA) for clinical investigation as a single agent or in combination with other therapeutic approaches, and is now known as PF ...

WebTrial Registration: ClinicalTrials.gov NCT00984763 Citation: Duncan CJA, Sheehy SH, Ewer KJ, Douglas AD, Collins KA, et al. (2011) Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS ONE 6(7): e22271. WebLGM Pharma is a US-based CpG ODN 7909 API supplier distributor. Ask about DMF, price & availability. See product details. ... Products currently covered by valid US Patents are …

WebAug 12, 2002 · CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and …

WebJan 1, 2006 · Coley also has pending US patent applications covering the specific sequence of CpG 7909 and its use to treat cancer, which, if issued, would be expected to expire … explain blackwood in bridgeWebOct 3, 2005 · CPG 7909 uses short, synthetic DNA-like molecules, known as CpG, to activate an anti-tumor immune system response. Krieg first described CpG in the mid-1990s as a result of pioneering research in ... b\\u0026b theatres operating companyWebJan 14, 2024 · Alternative Names: Agatolimod sodium; CpG 7909; CPG ODN 2006; CpG oligodeoxynucleotide 7909; PF-3512676; PF-676; ProMune Latest Information Update: … explain bodily injury coverageWebOur physicians in Central GA have been carefully selected for outstanding academic achievement, commitment to their patients, and quality of care. explain blood pressure readingWebMar 18, 2024 · CPG 7909 is an immunostimulatory synthetic oligodeoxynucleotide that functions as an adjuvant. It is designed to induce an enhanced immune response. Experimental: AV7909 Lot 2 Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. Groups 1 to 3 will each receive one of the three … explain bluetooth 3.0 plus edrWeb调节免疫反应的核酸成分专利检索，调节免疫反应的核酸成分属于·碳水化合物糖其衍生物专利检索，找专利汇即可免费查询专利，·碳水化合物糖其衍生物专利汇是一家知识产权数据服务商，提供专利分析，专利查询，专利检索等数据服务功能。 explain blitzing in footballWebAug 3, 2011 · Thus far, just one CpG oligonucleotide has completed phase 3 trials, CpG 7909. CpG 7909 (PF03512676) is a class B 24 nt agonist of TLR9 in B cells and pDCs [140]. Both phase 3 trials of CpG 7909 ... explain block diagram of microcomputer